Phase 2 N=47 Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder
PTSD
Primary: Changes in CAPS Scores. — 43.5; 51.1 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 2 N=49 Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
Head and Neck Cancer · Radiation Toxicity · Xerostomia
Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants
Phase 2 N=41 Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Define the Maximum Tolerated Dose (MTD) Using This Dose Schedule. — 20; 28.6; 33.3 Percentage subj w dose limiting toxicity
Phase 2 N=20 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants
Phase 2 N=22 Study of SB939 in Subjects With Myelofibrosis
Myeloproliferative Disorders
Primary: Participants With an Objective Response — 0; 0; 2 Participants
Phase 2 N=323 Provoked Craving Assessment
Smoking Dependence · Smoking
Primary: Change From Post-cue Baseline in Nicotine Craving Score at 5 Minutes — -41.8; -25.9 Score on a scale — p=<0.0001
Phase 2 N=101 Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
Pain Due to Osteoporosis
Primary: Pain (Subjective Symptom) — -37.8; -24.5; -40.5; -29.0 mm
Phase 2 N=238 Darbepoetin Alfa With or Without Intravenous (IV) Iron
Anemia · Non-Myeloid Malignancies
Primary: Number of Participants Who Achieved the Target Hemoglobin Level, by Darbepoetin Alfa Dose — 71; 82 Participants
Phase 2 N=126 Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of TIV — 84; 53; 81…
Phase 2 N=40 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Phase 2 N=40 ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
Healthy Males
Primary: Intratesticular Testosterone (IT-T) Level — 14; 3.7; 1.7; 18.4 ng/mL — p=<0.05
Phase 2 N=94 Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
Cocaine Dependence
Primary: Percent of Participants Reporting no Cocaine Craving — 64; 41 Percent of participants
Phase 2 N=80 VIVITROL as a Treatment for Cocaine and Alcohol Dependence
Cocaine Dependence · Alcohol Dependence
Primary: Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine. — 33.3; 31.7 Percentage of Participants
Phase 2 N=12 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease
Alzheimer's Disease · Aphasia · Dementia
Primary: Cognitive Assessment Task Scores Before, During and After rTMS. — 26.9; 13.3; 17.0 units on a scale